Literature DB >> 12710872

Comparison of the radiotoxicity of two alpha-particle-emitting immunoconjugates, terbium-149 and bismuth-213, directed against a tumor-specific, exon 9 deleted (d9) E-cadherin adhesion protein.

Matthias Miederer1, Christof Seidl, Gerd-Jürgen Beyer, David E Charlton, Sanja Vranjes-Duric, Jozef J Comor, Roswitha Huber, Tuomo Nikula, Christos Apostolidis, Christoph Schuhmacher, Karl-Friedrich Becker, Reingard Senekowitsch-Schmidtke.   

Abstract

We investigated the effects of the alpha-particle emitters (149)Tb and (213)Bi coupled to a tumor-specific antibody targeting the mutated delta 9 E-cadherin (d9 E-Cad) on single cells and cell pellets. The d9 mutation of the adhesion molecule E-cadherin is found in 10% of diffuse-type gastric cancers and is not expressed in normal tissue. Human breast cancer cells (MDA-MB-435S) transfected with d9 E-Cad or the wild-type E-cadherin gene were used to study the effects of anti-d9 E-Cad MAb coupled to (149)Tb and (213)Bi ((149)Tb-d9 MAb and (213)Bi-d9 MAb). The density of binding sites determined on transfected MDA tumor cells by Scatchard analysis and flow cytometry varied from 4 x 10(4) to 6 x 10(4) antigens per cell. Internalization of radioimmunoconjugates by cells expressing d9 E-Cad was less than 10% of bound antibody within 240 min. The effect of the radioimmunoconjugates on cell suspensions and cell pellets was quantified by [(3)H]thymidine incorporation, and the dose to the cell nuclei was determined using microdosimetric calculations. (149)Tb and (213)Bi immunoconjugates affected cells in suspension similarly. Significant differences in the proliferation capacity of d9 E-cadherin- and wild-type E-cadherin-expressing cells were observed at activity concentrations around 185 kBq/ml, corresponding to antibody concentrations between 200 ng/ml and 1000 ng/ml. Proliferation after incubation with (213)Bi-d9 MAb was 50% greater in pelleted wild-type E-Cad-expressing cells compared to wild-type E-Cad cells in suspension. In contrast, the proliferation of pelleted d9 E-Cad cells was similar to that of d9 E-Cad cells in suspension. For (149)Tb-d9 MAb, no significant difference was found between pelleted cells and cells in suspension for low activity concentrations. However, at high activity concentrations, (149)Tb-d9 MAb had only a small effect on pelleted cells. These in vitro studies demonstrate different effects of (149)Tb and (213)Bi conjugated to a tumor-specific antibody toward single cells and tumor cell pellets. Microdosimetric simulation of single cell survival after alpha-particle irradiation modeled the experimental results with reasonable accuracy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12710872     DOI: 10.1667/0033-7587(2003)159[0612:cotrot]2.0.co;2

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  11 in total

Review 1.  Radioimmunotherapy of solid tumors: searching for the right target.

Authors:  Hong Song; George Sgouros
Journal:  Curr Drug Deliv       Date:  2011-01       Impact factor: 2.565

Review 2.  Targeted alpha-therapy: past, present, future?

Authors:  Martin W Brechbiel
Journal:  Dalton Trans       Date:  2007-09-11       Impact factor: 4.390

3.  Cell death triggered by alpha-emitting 213Bi-immunoconjugates in HSC45-M2 gastric cancer cells is different from apoptotic cell death.

Authors:  Christof Seidl; Hedwig Schröck; Sabine Seidenschwang; Roswitha Beck; Ernst Schmid; Michael Abend; Karl-Friedrich Becker; Christos Apostolidis; Tuomo K Nikula; Elisabeth Kremmer; Markus Schwaiger; Reingard Senekowitsch-Schmidtke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-10-02       Impact factor: 9.236

Review 4.  Cancer radioimmunotherapy with alpha-emitting nuclides.

Authors:  Olivier Couturier; Stéphane Supiot; Marie Degraef-Mougin; Alain Faivre-Chauvet; Thomas Carlier; Jean-François Chatal; François Davodeau; Michel Cherel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-05       Impact factor: 9.236

5.  Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using 149Tb-rituximab.

Authors:  G-J Beyer; M Miederer; S Vranjes-Durić; J J Comor; G Künzi; O Hartley; R Senekowitsch-Schmidtke; D Soloviev; F Buchegger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-01-14       Impact factor: 9.236

Review 6.  Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The "Hopeful Eight".

Authors:  Romain Eychenne; Michel Chérel; Férid Haddad; François Guérard; Jean-François Gestin
Journal:  Pharmaceutics       Date:  2021-06-18       Impact factor: 6.321

7.  Non-invasive visualisation of the development of peritoneal carcinomatosis and tumour regression after 213Bi-radioimmunotherapy using bioluminescence imaging.

Authors:  H Matthias Buchhorn; Christof Seidl; Roswitha Beck; Dieter Saur; Christos Apostolidis; Alfred Morgenstern; Markus Schwaiger; Reingard Senekowitsch-Schmidtke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-01-06       Impact factor: 10.057

8.  Folate receptor targeted alpha-therapy using terbium-149.

Authors:  Cristina Müller; Josefine Reber; Stephanie Haller; Holger Dorrer; Ulli Köster; Karl Johnston; Konstantin Zhernosekov; Andreas Türler; Roger Schibli
Journal:  Pharmaceuticals (Basel)       Date:  2014-03-13

Review 9.  Systemic targeted alpha radiotherapy for cancer.

Authors:  Bj Allen
Journal:  J Biomed Phys Eng       Date:  2013-09-17

10.  Targeted therapy of osteosarcoma with radiolabeled monoclonal antibody to an insulin-like growth factor-2 receptor (IGF2R).

Authors:  David S Geller; Jonathan Morris; Ekaterina Revskaya; Mani Kahn; Wendong Zhang; Sajida Piperdi; Amy Park; Pratistha Koirala; Hillary Guzik; Charles Hall; Bang Hoang; Rui Yang; Michael Roth; Jonathan Gill; Richard Gorlick; Ekaterina Dadachova
Journal:  Nucl Med Biol       Date:  2016-07-30       Impact factor: 2.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.